Insights

Strategic funding Rising Series B activity and notable new investors (Hatteras Venture Partners, Eshelman Ventures, Lilly, Pharmacosmos, Cape Fear BioCapital) indicate strong validation and potential partnerships for co-development, licensing, or strategic investment discussions around INX-315.

Clinical momentum Lead CDK2 inhibitor INX-315 is advancing through active clinical trials for advanced breast and ovarian cancers, signaling near-term opportunities to engage with oncology-focused clinics, contract research organizations, and patient access programs.

Board and leadership access Recent appointments to the board, including independent directors with drug development expertise, create openings for advisory collaborations, key network introductions, and potential collaboration on translational research and trial design.

Geographic focus Headquartered in Research Triangle Park, NC, with a North Carolina funding and clinical development footprint, suggesting priority engagements with regional CROs, academic centers, and healthcare providers in the Southeast and East Coast markets.

Sustainability and scale Moderate but growing revenue and a mid-size venture-backed profile imply opportunities to offer manufacturing scale-up services, supply chain partnerships, and strategic manufacturing collaborations as INX-315 moves toward later-stage trials.

Similar companies to Incyclix Bio

Incyclix Bio Tech Stack

Incyclix Bio uses 8 technology products and services including WordPress, Shopify, Google Cloud, and more. Explore Incyclix Bio's tech stack below.

  • Content Management System
  • E-commerce
  • Infrastructure As A Service
  • jQuery Migrate
    Javascript Libraries
  • Priority Hints
    Performance
  • Platform As A Service
  • Team Collaboration
  • Nginx
    Web Servers

Media & News

Incyclix Bio's Email Address Formats

Incyclix Bio uses at least 1 email format:
Incyclix Bio Email FormatsExamplePercentage
FLast@incyclixbio.comJDoe@incyclixbio.com
100%

Frequently Asked Questions

What is Incyclix Bio's official website and social media links?

Minus sign iconPlus sign icon
Incyclix Bio's official website is incyclixbio.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Incyclix Bio generate?

Minus sign iconPlus sign icon
As of October 2026, Incyclix Bio's annual revenue is estimated to be $10M - $25M.

What is Incyclix Bio's SIC code and NAICS code?

Minus sign iconPlus sign icon
Incyclix Bio's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Incyclix Bio have currently?

Minus sign iconPlus sign icon
As of October 2026, Incyclix Bio has approximately 13 employees across 1 continents, including North America. Key team members include Co-Founder, Senior Vice President: J. E. B. Explore Incyclix Bio's employee directory with LeadIQ.

What industry does Incyclix Bio belong to?

Minus sign iconPlus sign icon
Incyclix Bio operates in the Biotechnology Research industry.

What technology does Incyclix Bio use?

Minus sign iconPlus sign icon
Incyclix Bio's tech stack includes WordPress, Shopify, Google Cloud, jQuery Migrate, Priority Hints, WP Engine, Box and Nginx.

What is Incyclix Bio's email format?

Minus sign iconPlus sign icon
Incyclix Bio's email format typically follows the pattern of FLast@incyclixbio.com. Find more Incyclix Bio email formats with LeadIQ.

How much funding has Incyclix Bio raised to date?

Minus sign iconPlus sign icon
As of October 2026, Incyclix Bio has raised $52M in funding. The last funding round occurred on Apr 08, 2026 for $11M.

When was Incyclix Bio founded?

Minus sign iconPlus sign icon
Incyclix Bio was founded in 2020.
Incyclix Bio logo

Incyclix Bio

Biotechnology ResearchNorth Carolina, United States11-50 Employees

Incyclix Bio, LLC is a biotechnology company focused on cell cycle control as a therapeutic approach to cancer. It is advancing INX-315, a potent and selective CDK2 inhibitor nearing clinical development, to address advanced and resistant cancers. The firm, founded by pioneers in CDK inhibitor discovery and development, emphasizes cyclin-dependent kinases as therapeutic targets across tumor types including ovarian, breast, and lung cancers and is based in Durham, North Carolina.

Operating within biotechnology research, the company develops therapies aimed at precision oncology by targeting CDKs. A recent development is the appointment of Kseniya Simpson to its board of directors in April 2026, expanding governance with a partner from Hatteras Venture Partners.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
11-50

Section iconFunding & Financials

  • $52M

    Incyclix Bio has raised a total of $52M of funding over 4 rounds. Their latest funding round was raised on Apr 08, 2026 in the amount of $11M as a Series B.

  • $10M - $25M

    Incyclix Bio's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.